Grp94-Specific Monoclonal Antibody to Counteract BRAF Inhibitor Resistance in BRAFV600E Melanoma

Journal of Translational Medicine - United Kingdom
doi 10.1186/1479-5876-13-s1-k12
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas

Oncotarget
Oncology
2016English

Inhibition of YAP Function Overcomes BRAF Inhibitor Resistance in Melanoma Cancer Stem Cells

Oncotarget
Oncology
2017English

809 Pou4f1 Promotes Braf Inhibitor Resistance by Reactivating Mapk Signaling Pathway in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma

iScience
Multidisciplinary
2019English

BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects

Current Cancer Drug Targets
Cancer ResearchDrug DiscoveryOncologyPharmacology
2014English

Antitumor Activity of the Selective Pan-Raf Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma

Cancer Research
Cancer ResearchOncology
2013English

Ineffective Anti PD-1 Therapy After BRAF Inhibitor Failure in Advanced Melanoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

Why Do We Need a New BRAF-MEK Inhibitor Combination in Melanoma?

Oncology in Clinical Practice
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy